Saturday 17 October 2026
Export CNTB’s income statement to Excel — free account
Connect Biopharma Holdings Limited Sponsored ADR
CNTB Healthcare Biotechnology
Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024. In the quarter to June 2026, revenue grew 296.6%, EPS fell 17.4%, free cash flow fell 23.5% and total debt fell 61.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.91
0.00
0.00%
Follow CNTB
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | — | — | 0.81 | (5.94) |
P/S ratio |
— | — | — | — | — | — | — | 0.00 | 79.23 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | — | 3.74 | (22.77) |
P/FCF ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | — | — | — | 681.78 |
P/Operating CF |
— | — | — | — | — | — | — | (32.86) | (13.95) |
P/B ratio |
— | — | — | — | — | — | — | 0.83 | 3.74 |
Price to Tangible BV |
— | — | — | — | — | — | — | 0.83 | 3.74 |
EV/Sales |
— | — | — | — | — | — | — | 0.00 | 57.04 |
EV/EBITDA |
— | — | — | — | — | — | — | 0.25 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | — | 0.74 | (2.21) |
EV/FCF |
— | — | — | — | — | — | — | 0.71 | (2.19) |
Quick Ratio |
— | 67.82 | 12.40 | 27.81 | 15.30 | 9.97 | 4.85 | 11.46 | 3.74 |
Current Ratio |
— | 70.44 | 13.24 | 27.81 | 15.30 | 9.97 | 4.85 | 11.46 | 3.74 |
Net Debt/EBITDA |
— | (2.13) | (2.62) | 5.21 | 2.72 | 1.29 | 1.73 | 4.30 | 0.77 |
Debt/Assets |
0.00% | 126.71% | 172.82% | 0.03% | 0.01% | 0.14% | 0.14% | 0.02% | 0.66% |
Debt/Equity |
— | (4.52) | (2.16) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.23 | 0.00 |
Operating CF/Net income |
— | 0.90 | 0.54 | 0.21 | 0.42 | 0.86 | 0.77 | 1.51 | 0.92 |
Capex/Depreciation |
— | 0.00 | 0.00 | (10.60) | (6.19) | (4.27) | 3.98 | (1.14) | (0.61) |
Interest Coverage |
— | (11.35) | (121.12) | (68.42) | (14,148.29) | (5,681.71) | (3,002.43) | — | — |
| — | 37.93% | 79.58% | 119.48% | (355.92%) | (54.96%) | (47.96%) | (16.14%) | (82.72%) | |
| — | (35.21%) | (40.82%) | (108.69%) | (89.64%) | (50.78%) | (41.21%) | (13.67%) | (70.51%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (1,355.35%) | (1,401.74%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (18.05%) | (50.17%) | (75.97%) | (76.93%) | (81.37%) | (61.17%) | (16.89%) | (134.91%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 45.61 | 37,566.48 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 112.38% | 59,059.38% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 73.86% | 31,781.25% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 25.84% | 5,821.88% |
Graham Net Nets |
— | — | — | — | — | — | — | 1.15 | 0.23 |
Graham Number |
— | — | — | — | — | — | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | (80.59%) | (35.46%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | (32.36%) | (32.90%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | 0.00 |
Operating CF per Share |
— | (0.18) | (0.23) | (0.86) | (1.64) | (1.84) | (0.87) | (0.43) | (0.92) |
Capex per Share |
— | 0.00 | 0.00 | (0.08) | (0.08) | (0.08) | 0.05 | (0.01) | (0.01) |
Free Cash Flow per Share |
— | (0.18) | (0.23) | (0.94) | (1.71) | (1.92) | (0.81) | (0.44) | (0.93) |
Cash per Share |
— | 1.09 | 0.85 | 5.27 | 5.13 | 2.77 | 2.15 | 1.70 | 0.80 |
Shareholders Equity per Share |
— | (0.32) | (0.74) | (5.28) | 5.22 | 2.86 | 1.84 | 1.67 | 0.75 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.32) | (0.74) | (5.28) | 5.22 | 2.86 | 1.84 | 1.67 | 0.75 |
Free Cash Flow |
— | (10.43) | (13.06) | (27.96) | (89.43) | (105.92) | (44.88) | (24.36) | (51.64) |
Working Capital |
— | 64.00 | 48.15 | 156.14 | 257.14 | 140.16 | 97.26 | 88.50 | 37.32 |
Capital Expenditures |
— | (0.18) | (0.16) | (2.34) | (3.96) | (4.40) | 2.86 | (0.75) | (0.43) |
Net Current Asset Value |
— | (19.66) | (44.23) | (161.38) | 256.33 | 139.26 | 96.68 | 87.84 | 36.83 |
EV/EBIT |
— | — | — | — | — | — | — | 0.00 | 0.00 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 6.75 |
Price to Operating Income |
— | — | — | — | — | — | — | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.21 | 0.23 | 0.21 | 0.07 | 0.21 | 0.17 | 0.16 | 0.18 |
Cash ROIC |
— | (8.17%) | (13.28%) | 12,264.91% | (16.56%) | (34.15%) | (20.40%) | (13.11%) | (59.57%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 6.94 | 0.01 |
Accounts Payable Turnover |
— | 0.05 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 1,915.29 | 10,447.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | 6.29 | 6.29 | 5.39 | 3.81 | 3.75 | 4.92 |
Average Payables |
— | 1.89 | 1.89 | 3.52 | 8.26 | 12.34 | 7.07 | 1.28 | 1.15 |
Average Assets |
— | 33.03 | 59.78 | 109.88 | 228.66 | 232.53 | 150.69 | 114.33 | 78.68 |
Average Common Equity |
— | (30.67) | (30.67) | (99.95) | 57.59 | 214.87 | 129.49 | 96.83 | 67.07 |
Columns are period end dates